According to the European Society of Cardiology (ESC) guidelines for angiotensin-converting enzyme (ACEI), mineralocorticoid receptor antagonist (MRA), and β receptor blocker, drugs are recommended for the treatment of heart failure with a reduced ejection fraction [70]. This evidence concerns the gene NR3C2 and heart failure.